Keros Therapeutics (KROS) Change in Accured Expenses (2019 - 2025)

Keros Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$4.4 million for Q4 2025.

• Quarterly Change in Accured Expenses fell 241.03% year-over-year to -$4.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$10.1 million (down 443.19% YoY) and the FY2025 annual result came in at -$10.1 million, down 443.19% from the prior year.
• Change in Accured Expenses was -$4.4 million for Q4 2025 at Keros Therapeutics, up from -$4.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $8.7 million in Q3 2024 and bottomed at -$5.4 million in Q1 2024.
• A 5-year average of $302600.0 and a median of $317500.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 4494.85% — and 2023, when it plunged 647.65%.
• Keros Therapeutics' Change in Accured Expenses stood at -$97000.0 in 2021, then surged by 4494.85% to $4.3 million in 2022, then jumped by 35.75% to $5.8 million in 2023, then slumped by 122.45% to -$1.3 million in 2024, then plunged by 241.03% to -$4.4 million in 2025.
• Business Quant data shows KROS's Change in Accured Expenses at -$4.4 million in Q4 2025, -$4.8 million in Q3 2025, and $2.7 million in Q2 2025.